AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02947243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR distraction via Oculus Rift
Description: In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
Study NCT01260155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
Study NCT01260155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
Study NCT01260155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment C: 40 mg new tablet formulation administered with food
Study NCT00542620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
Study NCT00542620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
Study NCT00542620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
Study NCT00542620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
Study NCT03644628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of anterior and apical pelvic organ prolapse
Description: Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
Study NCT03644628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic repair of anterior and apical pelvic organ prolapse
Description: Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
Study NCT01007214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Elective prostatectomy
Study NCT00929955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
Study NCT00929955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
Study NCT00929955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU
Study NCT00214461 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine diluent buffer (Placebo)
Description: 0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
Study NCT00214461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile toxoid vaccine (2 µg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
Study NCT00214461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile toxoid vaccine (10 µg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
Study NCT00214461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile toxoid vaccine (50 µg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
Study NCT04628923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QUADRATUS LUMBORUM BLOCK
Description: QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH
Study NCT01484782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) automated calls
Description: Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
Study NCT03118596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
Study NCT02947243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: As per unit's protocol
Study NCT00553280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Study NCT03118596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Protector
Description: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
Study NCT01609595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium 2,2 dimethylbutyrate
Description: Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
Study NCT02689323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation
Study NCT01688050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® TX2® Low Profile Endovascular Graft
Description: Treatment of Blunt thoracic aortic injuries (BTAIs)
Study NCT00927368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance alone
Description: The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
Study NCT00927368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance and needle stimulation
Description: For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
Study NCT00927368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance and catheter stimulation
Description: The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
Study NCT02624492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Study NCT02624492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GemOx
Study NCT02624492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02624492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GemOx
Study NCT03909360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drainage tube
Description: sub-hepatic drainage tube for laparoscopic cholecystectomy
Study NCT01019018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subtenon block
Description: subtenon block with stevens cannula
Study NCT01019018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subtenon block
Description: subtenon block with Olive tip cannula cannula
Study NCT00858429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
Study NCT00858429 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
Study NCT00783393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
Study NCT04428411 — intervention group
Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study NCT01163786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
Study NCT02805205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study NCT03942315 — intervention group
Intervention type: OTHER
Intervention: Data collection from standard follow-up after liver transplant
Description: All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.
Study NCT04137783 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study, only observation.
Study NCT04444856 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
Study NCT01654900 — intervention group
Intervention type: OTHER
Intervention: No intervention in this study
Study NCT00132730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 2.5 mg
Study NCT00132730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 1.25 mg
Study NCT00132730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 0.75 mg
Study NCT00132730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-0873
Study NCT00132730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-0873
Study NCT00132730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Care
Study NCT00132730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT00781157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine bolus
Description: The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose.
Study NCT03471078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Oral avatrombopag tablet
Study NCT01554579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: BID
Study NCT01554579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Placebo
Study NCT02303717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary stent implantation
Study NCT02303717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary stent implantation
Study NCT02303717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Description: Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
Study NCT02303717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy
Description: Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
Study NCT03850184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Exercise in Mental Illness Questionnaire (EMIQ)
Description: Questionnaire assessing prescription behaviour, knowledge, barriers and behaviour of physical activity in mental health professionals
Study NCT03175341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
Study NCT03175341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: 100 ml normal saline 0.9%
Study NCT03979326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
Study NCT02266030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Pletaal as an active drug
Study NCT02266030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin as an active comparator
Study NCT01808612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT03234569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sonoHSG
Description: This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
Study NCT03471078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator tablet
Study NCT01881048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Given PO
Study NCT01881048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO
Study NCT01808612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03621579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
Study NCT01276730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon, Retinoic Acid and radiation
Description: Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
Study NCT02816879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo anal cytology collection
Study NCT02816879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04628546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Parenting Young Children Check-up Initial Check-up and Text Messages
Description: Parents assigned to the intervention condition will go through the Initial Check-up, which is a brief intervention that uses motivational content to promote use of the Parenting Young Children Check-up parenting education website. They will also receive text messages and a brochure to connect them to the parenting education website.
Study NCT04628546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Parenting Young Children Check-up Flier and Text Messages
Description: Parents assigned to the control condition will not go through the Parenting Young Children Check-up Initial Check-up. They will only go through assessment and then see a brief flier about the Parenting Young Children. Like the intervention condition, they will also receive text messages and a brochure to connect them to the Parenting Young Children Check-up parenting education website.
Study NCT01827631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 capsule
Description: Swedish Orange, size 0, hard gelatine capsules
Study NCT01835119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gum
Description: gum
Study NCT01648257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Na Salt Tablets
Description: Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
Study NCT01648257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Free Acid Nanomilled Capsules
Description: Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
Study NCT01648257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Free Acid Micronized Capsules
Description: Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
Study NCT04457960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-66525433
Description: Participants will receive JNJ-66525433 oral capsules.
Study NCT04457960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo oral capsules.
Study NCT04401033 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephonic medical visit
Description: The patient will receive a telephonic call passing a medical visit
Study NCT04401033 — intervention group
Intervention type: PROCEDURE
Intervention: Gastrointestinal endoscopy
Description: Upper or lower GI endoscopy according to clinical practice and current guidelines
Study NCT04401033 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal ultrasound
Description: Diagnostic abdominal ultrasound according to the current guidelines
Study NCT02953145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisseel
Description: Tisseel will be applied to open areas lateral to the cleft palate repair
Study NCT01351441 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication adherence consultation
Description: Patients will be counseled in person on day 0 then telephonically every month after until day 365.
Study NCT01351441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medication problems assessment
Description: Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
Study NCT01276730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin and radiation
Description: Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.